Teladoc Health, Inc. (TDOC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.42% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
- Evergreen Nephrology Appoints Brian Palo as Chief Financial Officer
- Connected Health & Safety Association Annual Conference Highlights Industry Growth and the Future of Connected Care
- Teladoc Health Announces Chief Legal Officer Transition
- The Bull Case For Teladoc Health (TDOC) Could Change Following Weak Q2 Results And Lowered Guidance
- Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade
- Q2 Earnings Highs And Lows: Teladoc (NYSE:TDOC) Vs The Rest Of The Online Marketplace Stocks
- Why Teladoc (TDOC) Outpaced the Stock Market Today
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Teladoc Health, Inc..
Full TDOC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.